Kalaris Therapeutics Inc
KLRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1,117 |
| Gross Profit | $0 | $0 | $0 | -$1,117 |
| % Margin | – | – | – | – |
| R&D Expenses | $12,340 | $11,707 | $11,763 | $119,618 |
| G&A Expenses | $0 | $1,757 | $2,243 | $0 |
| SG&A Expenses | $42,916 | $1,757 | $2,243 | $49,083 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $55,256 | $13,464 | $14,006 | $168,701 |
| Operating Income | -$55,256 | -$13,464 | -$14,006 | -$169,818 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3,513 | -$1,235 | -$1,479 | -$1,137 |
| Pre-Tax Income | -$58,769 | -$14,699 | -$15,485 | -$170,955 |
| Tax Expense | $0 | $0 | $0 | $1,007 |
| Net Income | -$58,769 | -$14,699 | -$15,485 | -$171,962 |
| % Margin | – | – | – | – |
| EPS | -11.73 | -42.089 | -50.621 | -63 |
| % Growth | 72.1% | 16.9% | 19.6% | – |
| EPS Diluted | -11.73 | -42.089 | -50.621 | -63 |
| Weighted Avg Shares Out | 5,008 | 4,524 | 3,333 | 2,730 |
| Weighted Avg Shares Out Dil | 5,008 | 4,524 | 3,333 | 2,730 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,486 | $0 | $0 | $1,315 |
| Interest Expense | $0 | $687 | $235 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1,117 |
| EBITDA | -$58,769 | -$14,012 | -$15,250 | -$169,838 |
| % Margin | – | – | – | – |